Appearing as a noteworthy breakthrough in the fight against obesity, the drug is capturing considerable attention . This treatment combines properties of two established GLP-1 receptor agonists, semaglutide , and an new glucose-dependent peptide component. Early clinical results have shown significant body loss in people with obesity , possibly pr